Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $24,689 | $27,305 | $27,281 | $27,116 | $28,754 |
| Gross Profit | $5,930 | $20,704 | $21,624 | $20,618 | $22,503 |
| Operating Income | $4,071 | $9,918 | $7,330 | $7,605 | $1,662 |
| Net Income | $123 | $6,225 | $4,592 | $5,665 | $480 |
Over the five-year period, Gilead Sciences’ revenue increased steadily from USD 24,689 million in 2020 to USD 28,754 million in 2024, indicating modest overall top‐line growth. The gross profit shows remarkable improvement starting in 2021, leaping from USD 5,930 million in 2020 to USD 20,704 million, and then continuing at elevated levels through 2024. This major increase in gross profit suggests either a significant change in product mix, pricing strategy, or lower production costs. However, while revenue and gross profit trended upward, operating income presented a contrasting picture. Operating income peaked in 2021 at USD 9,918 million but then declined in subsequent years—falling to USD 7,330 million in 2022, slightly rebounding to USD 7,605 million in 2023, and then dropping sharply to USD 1,662 million in 2024, marking a significant year-over-year decline of over 70% compared to 2023. Net income trends also reveal significant volatility. After recording a very low net income of USD 123 million in 2020, the company rebounded to USD 6,225 million in 2021, reflecting robust profitability improvements, only to see a decline to USD 4,592 million in 2022 and a moderate recovery to USD 5,665 million in 2023. The dramatic drop to USD 480 million in 2024 raises concerns about underlying cost pressures, increased expenses, or potential one-time factors impacting operating efficiency. Overall, while Gilead has maintained revenue and gross profit growth, the successive declines in operating and net income—particularly in 2024—suggest that the company may be facing challenges in managing costs or sustaining operational efficiencies in a competitive and evolving biopharmaceutical environment.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.